These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

156 related items for PubMed ID: 10229308

  • 1. The effect of gliclazide on plasma insulin, intact and 32/33 split proinsulin in South Asian subjects with Type 2 diabetes mellitus.
    Ammari F, Davies MJ, Koppiker N, Gregory R, Burden AC.
    Diabet Med; 1999 Feb; 16(2):142-6. PubMed ID: 10229308
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Relative hyperproinsulinemia of NIDDM persists despite the reduction of hyperglycemia with insulin or sulfonylurea therapy.
    Rachman J, Levy JC, Barrow BA, Manley SE, Turner RC.
    Diabetes; 1997 Oct; 46(10):1557-62. PubMed ID: 9313749
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Immunoradiometric assay of insulin, intact proinsulin and 32-33 split proinsulin and radioimmunoassay of insulin in diet-treated type 2 (non-insulin-dependent) diabetic subjects.
    Clark PM, Levy JC, Cox L, Burnett M, Turner RC, Hales CN.
    Diabetologia; 1992 May; 35(5):469-74. PubMed ID: 1521730
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. A higher proinsulin response to glucose loading predicts deteriorating fasting plasma glucose and worsening to diabetes in subjects with impaired glucose tolerance.
    Inoue I, Takahashi K, Katayama S, Harada Y, Negishi K, Ishii J, Shibazaki S, Nagai M, Kawazu S.
    Diabet Med; 1996 Apr; 13(4):330-6. PubMed ID: 9162608
    [Abstract] [Full Text] [Related]

  • 16. A long-term comparison of pioglitazone and gliclazide in patients with Type 2 diabetes mellitus: a randomized, double-blind, parallel-group comparison trial.
    Charbonnel BH, Matthews DR, Schernthaner G, Hanefeld M, Brunetti P, QUARTET Study Group.
    Diabet Med; 2005 Apr; 22(4):399-405. PubMed ID: 15787663
    [Abstract] [Full Text] [Related]

  • 17. Effect of repaglinide and gliclazide on glycaemic control, early-phase insulin secretion and lipid profiles in.
    Zhang H, Bu P, Xie YH, Luo J, Lei MX, Mo ZH, Liao EY.
    Chin Med J (Engl); 2011 Jan; 124(2):172-6. PubMed ID: 21362360
    [Abstract] [Full Text] [Related]

  • 18. The effect of sulphonylurea therapy on skeletal muscle glycogen synthase activity and insulin secretion in newly presenting type 2 (non-insulin-dependent) diabetic patients.
    Johnson AB, Argyraki M, Thow JC, Jones IR, Broughton D, Miller M, Taylor R.
    Diabet Med; 1991 Apr; 8(3):243-53. PubMed ID: 1828740
    [Abstract] [Full Text] [Related]

  • 19. Genetic cause of hyperglycaemia and response to treatment in diabetes.
    Pearson ER, Starkey BJ, Powell RJ, Gribble FM, Clark PM, Hattersley AT.
    Lancet; 2003 Oct 18; 362(9392):1275-81. PubMed ID: 14575972
    [Abstract] [Full Text] [Related]

  • 20. Intact proinsulin, des 31,32 proinsulin, and specific insulin concentrations among nondiabetic and diabetic subjects in populations at varying risk of type 2 diabetes.
    Nagi DK, Knowler WC, Mohamed-Ali V, Bennett PH, Yudkin JS.
    Diabetes Care; 1998 Jan 18; 21(1):127-33. PubMed ID: 9538983
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.